FILING ANALYSIS · THURSDAY, NOVEMBER 5
Disc Medicine, Inc. IRON — 8-K: Results of Operations and Financial Condition
neutral
Disc Medicine's pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) met all primary and secondary endpoints, and the company plans to resubmit a New Drug Application (NDA) by the end of 2026, but the recent public offering of approximately $486 million may lead to dilution
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →